Hi there, Thank you for subscribing to MarketBeat Daily Ratings. We're excited to have you onboard! Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. Please take a moment to confirm your subscription by clicking the link below. You may not receive your daily ratings newsletter without confirming your subscription. Click Here to Confirm Your Subscription to MarketBeat Daily Ratings Thank you again for subscribing. We look forward to being an important part of your investing journey.
Matthew Paulson
Founder and CEO, MarketBeat.
Confirm Your Subscription to MarketBeat Daily Ratings Here
Today's Featured Content Biotech Breakouts: 3 Stocks With Massive Upside PotentialWritten by Chris Markoch. Published 9/17/2025. 
Key Points - Viking stock is down, but still has major upside in the obesity drug market.
- ImmunityBio advances Anktiva beyond bladder cancer with new trial results.
- Maze Therapeutics rallies on early-stage data with more catalysts ahead.
Investing in biotechnology stocks is complex, given the intricate science behind their drug candidates. These names are notoriously volatile, with double-digit swings in either direction a common occurrence. Despite the risks, biotech stocks offer a compelling long-term risk-reward profile. For patient investors willing to see their positions through the clinical trial process, the potential payoff in these three names could be substantial. Viking: An Obesity Challenger with Big Upside George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert.
He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves. Click here to see what's coming before the story goes mainstream. Viking Therapeutics Inc. (NASDAQ: VKTX) benefited in 2024 from the surge in popularity of GLP-1 weight-loss drugs. However, in 2025 the stock has declined more than 40%, including roughly a 20% drop following its August clinical trial update. Those results weren't disappointing—patients averaged a 12.2% weight loss, and Viking did not fail the trial by any measure. Investors were concerned that the most significant losses occurred at the highest dosage—unlike competitors reporting similar or better results at lower doses—and by a 28% dropout rate, suggesting more side effects than preferred. Analysts believe the sell-off may be overdone: the consensus price target is $87.50, implying about 270% upside from current levels. The market for obesity drugs is large enough to support more than just the two giants—Novo Nordisk and Eli Lilly—which makes this an opportune time for conviction investors to start accumulating. From a technical standpoint, VKTX appears to be bottoming: the relative strength index (RSI) sits near 34—approaching oversold territory—and the MACD suggests bearish momentum is fading. After forming a death cross in late August, traders should watch for a golden cross as a sign of renewed momentum. 
ImmunityBio: A Penny Stock with Serious Potential ImmunityBio Inc. (NASDAQ: IBRX) is up roughly 8.4% in 2025, with most of that rally coming in the past month. In late August, the company reported that all five glioblastoma patients in its pilot study "attained 100% disease control" using a regimen that includes its ANKTIVA therapy. ANKTIVA earned FDA approval in April 2024 for bladder cancer and is now in trials for other cancer indications. The company is also exploring ANKTIVA as a potential therapy for HIV and Long COVID. This broad utility makes ANKTIVA one of the most exciting immunotherapy drugs in development. Analysts peg IBRX at a consensus price target of $10.75, implying over 280% upside. In the near term, caution may be prudent: IBRX trades above its 200-day simple moving average and carries an RSI of 76—a historically resistant level. Investors might wait for a modest pullback before initiating a position. While a pullback could present a better entry point, the long-term thesis holds: if ANKTIVA proves effective across multiple indications, IBRX could graduate from penny stock status to biotech heavyweight. 
Maze Therapeutics: Early Success in Rare Diseases Maze Therapeutics Inc. (NASDAQ: MAZE) went public in February 2025. Since its debut, the stock has climbed about 86%, and analysts see further upside. On Sept. 11, the company released positive Phase 1 results for MZE782, its lead candidate targeting phenylketonuria (PKU) and chronic kidney disease (CKD). These findings establish proof of mechanism for a potent oral SLC6A19 inhibitor, paving the way for a Phase 2 trial. Of course, FDA approval is years away and not guaranteed. Still, analysts remain optimistic: HC Wainwright is the most bullish, assigning a $50 price target—more than double current levels. Rapid parabolic moves often warrant caution: MAZE's RSI is pushing into overbought territory. However, recent support around $22.40 could indicate bullish momentum if it holds. MAZE offers investors exposure to rare disease therapeutics—an area of biotech with strong pricing power and less competition. If clinical progress continues, the stock could see sustained gains. 
| 
